Conference Call Scheduled for August 31 at 8:00 a.m. ET with Pre-Registration Required SHANGHAI and GAITHERSBURG, Md. , Aug. 6, 2020 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of

SHANGHAI and GAITHERSBERG, Md., Aug. 4, 2020 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that the China National Medical Products Administration

SHANGHAI and GAITHERSBERG, Md., July 28, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced the appointment of Mr.

SHANGHAI and GAITHERSBURG, Md. , July 15, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that its Board of Directors has authorized a stock

SHANGHAI and GAITHERSBURG, Md. , June 12, 2020 /PRNewswire/ --  I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, will be presenting preclinical data on a newly developed, novel asset

SHANGHAI and GAITHERSBURG, Md. , May 29, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical

- Though blinded, there is a trend for correlation between clinical improvement and reduced levels of some disease related cytokines - Data monitoring committee (DMC) reviewed the clinical data and unanimously recommended proceeding to part 2 of the study and endorsed the change of low dose

- I-Mab to initiate Phase 2 clinical trial in glioblastoma multiforme (GBM) in China - I-Mab and Genexine expand collaboration for development of TJ107/HyLeukin-7™ SHANGHAI, GAITHERSBURG, Md. and SEOUL, South Korea , May 21, 2020 /PRNewswire/ --  I-Mab (NASDAQ: IMAB), a clinical-stage

SHANGHAI and ROCKVILLE, Md. , May 20, 2020 /PRNewswire/ -- I-Mab (NASDAQ:IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly

SHANGHAI and ROCKVILLE, Md. , May 13, 2020 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, today